Pfizer Inc

PFE-N

NYSE:PFE

38.29
0.26 (0.68%)
Pfizer Inc. is an American pharmaceutical corporation headquartered in New York City, with its research headquarters in Groton, Connecticut. Pfizer is considered one of the world's largest pharmaceutical companies.
More at Wikipedia

Analysis and Opinions about PFE-N

Signal
Opinion
Expert
PAST TOP PICK
PAST TOP PICK
December 5, 2019
(A Top Pick Feb 08/19, Down 7%) All the drugs have been moving spectacularly. There is a lot of value. His model price is 48.79 or a 28% upside. If we have a fall, these stocks will do very well.
Pfizer Inc (PFE-N)
December 5, 2019
(A Top Pick Feb 08/19, Down 7%) All the drugs have been moving spectacularly. There is a lot of value. His model price is 48.79 or a 28% upside. If we have a fall, these stocks will do very well.
Brian Acker, CA
Chief Executive Officer, President and Chief Inves, Acker Finley Inc.
Price
$38.030
Owned
Yes
PAST TOP PICK
PAST TOP PICK
November 21, 2019
(A Top Pick Dec 06/18, Down 13%) Under pressure due to patent loss and divesting off-patent division. Dividend is 3.9% and looks secure. Political noise has hurt healthcare. This is an opportunity. Starting to launch potential blockbuster drugs.
Pfizer Inc (PFE-N)
November 21, 2019
(A Top Pick Dec 06/18, Down 13%) Under pressure due to patent loss and divesting off-patent division. Dividend is 3.9% and looks secure. Political noise has hurt healthcare. This is an opportunity. Starting to launch potential blockbuster drugs.
Stan Wong
Director & Portfolio Manager, Private Wealth Management, ScotiaMcleod
Price
$37.740
Owned
Yes
PAST TOP PICK
PAST TOP PICK
November 19, 2019
(A Top Pick Sep 09/19, Up 4%) He doesn't see upside in the drug space. He won't sell it, but won't add to it. This sector will be quiet as others rally. Hold.
Pfizer Inc (PFE-N)
November 19, 2019
(A Top Pick Sep 09/19, Up 4%) He doesn't see upside in the drug space. He won't sell it, but won't add to it. This sector will be quiet as others rally. Hold.
Elliott Fishman
Director of U.S. and international equity trading, Trading Services Group, Scotia Wealth
Price
$37.660
Owned
Yes
HOLD
HOLD
October 24, 2019
Dropped off with the spinoff. Very good dividend. Undervalued here because of political pressure. That's an opportunity. Healthcare companies tend to do well when the economic cycle matures. Be patient. Value stocks are emerging from their underperformance. Yield is 4%. (Analysts’ price target is $41.77)
Pfizer Inc (PFE-N)
October 24, 2019
Dropped off with the spinoff. Very good dividend. Undervalued here because of political pressure. That's an opportunity. Healthcare companies tend to do well when the economic cycle matures. Be patient. Value stocks are emerging from their underperformance. Yield is 4%. (Analysts’ price target is $41.77)
Stan Wong
Director & Portfolio Manager, Private Wealth Management, ScotiaMcleod
Price
$0.000
Owned
Yes
WAIT
WAIT
October 22, 2019
He liked this before, but has suffered a setback. The MFV is 37% higher than the present price. The earnings forecasts are rolling over, which worries him--it's a warning of bad things to come. He wouldn't buy this unless it fell to $30. Pays a 4% yield. Wait.
Pfizer Inc (PFE-N)
October 22, 2019
He liked this before, but has suffered a setback. The MFV is 37% higher than the present price. The earnings forecasts are rolling over, which worries him--it's a warning of bad things to come. He wouldn't buy this unless it fell to $30. Pays a 4% yield. Wait.
Ross Healy
Chairman, Strategic Analysis Corp
Price
$36.430
Owned
No
DON'T BUY
DON'T BUY
October 17, 2019

Real topline struggles over the past decade. Blockbusters go off patent and have to be replaced. Like bailing a leaky boat. You can only cut costs to make money for so long. If he had to pick one, he'd pick Merck. Their pipeline is superior to peers, and well managed. But he wouldn't own the industry at this point in the cycle.

Pfizer Inc (PFE-N)
October 17, 2019

Real topline struggles over the past decade. Blockbusters go off patent and have to be replaced. Like bailing a leaky boat. You can only cut costs to make money for so long. If he had to pick one, he'd pick Merck. Their pipeline is superior to peers, and well managed. But he wouldn't own the industry at this point in the cycle.

Gordon Reid
President, GoodReid Investment Counsel
Price
$36.500
Owned
Unknown
DON'T BUY
DON'T BUY
September 24, 2019
Weak in the healthcare space. It's currently at support level, and it is entering seasonal weakness in mid-October.
Pfizer Inc (PFE-N)
September 24, 2019
Weak in the healthcare space. It's currently at support level, and it is entering seasonal weakness in mid-October.
Brooke Thackray
Research Analyst, Horizons ETFs (Canada) Inc.
Price
$36.015
Owned
Unknown
TOP PICK
TOP PICK
September 16, 2019
He's bought and sold this at $43. They're Upjohn division is merging with Mylan and will spin it out. This will likely lead to the stock returning to the mid-$40's (Analysts’ price target is $42.75)
Pfizer Inc (PFE-N)
September 16, 2019
He's bought and sold this at $43. They're Upjohn division is merging with Mylan and will spin it out. This will likely lead to the stock returning to the mid-$40's (Analysts’ price target is $42.75)
Bruce Murray
CEO & Chief Investment Officer, The Murray Wealth Group
Price
$36.830
Owned
No
TOP PICK
TOP PICK
September 6, 2019
It has long term support levels. At a great spot, and it is consolidating well. Would take advantage of the pullback here. The risk is to go up not down.
Pfizer Inc (PFE-N)
September 6, 2019
It has long term support levels. At a great spot, and it is consolidating well. Would take advantage of the pullback here. The risk is to go up not down.
Elliott Fishman
Director of U.S. and international equity trading, Trading Services Group, Scotia Wealth
Price
$36.500
Owned
No
DON'T BUY
DON'T BUY
August 22, 2019

He would not buy it at this point. They recently agreed to by Mylan and with Teva have been challenged on pricing of their generic drugs. It has grown through cost cutting. Revenue growth is muted at best.

Pfizer Inc (PFE-N)
August 22, 2019

He would not buy it at this point. They recently agreed to by Mylan and with Teva have been challenged on pricing of their generic drugs. It has grown through cost cutting. Revenue growth is muted at best.

Gordon Reid
President, GoodReid Investment Counsel
Price
$34.340
Owned
Unknown
DON'T BUY
DON'T BUY
August 20, 2019
The US healthcare system is under attack by politicians until the election. Trump wants to put them out of business, so why mess with this space? Patent expirations are another hurdle.
Pfizer Inc (PFE-N)
August 20, 2019
The US healthcare system is under attack by politicians until the election. Trump wants to put them out of business, so why mess with this space? Patent expirations are another hurdle.
John O'Connell, CFA
Chairman and CEO, Davis Rea
Price
$34.610
Owned
Unknown
DON'T BUY
DON'T BUY
August 13, 2019

The PFE-N non-patent drugs will be dilutive for earnings in the short term. She prefers either JNJ-N or ABT-N

Pfizer Inc (PFE-N)
August 13, 2019

The PFE-N non-patent drugs will be dilutive for earnings in the short term. She prefers either JNJ-N or ABT-N

Christine Poole
CEO & Managing Director, GlobeInvest Capital Management
Price
$35.200
Owned
No
WATCH
WATCH
July 30, 2019
They were badly hit with the end of patent protection on several of their drugs. Viagara is coming up for expiry as well. He does not own it. It is a well run company and he continue to expect the dividend to grow as well. They announced an entry into the generic drug space, which may be confusing investors right now. He would hold off for a while.
Pfizer Inc (PFE-N)
July 30, 2019
They were badly hit with the end of patent protection on several of their drugs. Viagara is coming up for expiry as well. He does not own it. It is a well run company and he continue to expect the dividend to grow as well. They announced an entry into the generic drug space, which may be confusing investors right now. He would hold off for a while.
Bruce Murray
CEO & Chief Investment Officer, The Murray Wealth Group
Price
$38.790
Owned
No
BUY
BUY
July 26, 2019

Pfizer vs. Merck He owns both, which both score well in price momentum, high ROE, great balance sheet, pay a sustianble yield and are stable stocks. Merck has slightly better valuation metrics, but both stocks are very similar.

Pfizer Inc (PFE-N)
July 26, 2019

Pfizer vs. Merck He owns both, which both score well in price momentum, high ROE, great balance sheet, pay a sustianble yield and are stable stocks. Merck has slightly better valuation metrics, but both stocks are very similar.

Jason Mann
CIO & Co-Founder, Edgehill Patners
Price
$43.090
Owned
Yes
HOLD
HOLD
July 17, 2019
It's a machine that makes acquisitions which generate revenues worldwide. However, they lack growth and a presence in oncology though they recenly made an aquisition that can help growth. Expect modest growth, but limited downside too if a clinical trial fails. Good dividend and balance sheet. Good to hol.
Pfizer Inc (PFE-N)
July 17, 2019
It's a machine that makes acquisitions which generate revenues worldwide. However, they lack growth and a presence in oncology though they recenly made an aquisition that can help growth. Expect modest growth, but limited downside too if a clinical trial fails. Good dividend and balance sheet. Good to hol.
Paul MacDonald
Chief Investment Officer & Portfolio Manager, Harvest Portfolios Group
Price
$42.740
Owned
Yes
Showing 1 to 15 of 667 entries